Short answer
Beam Therapeutics Inc. (BEAM) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $307,000 (down 96.8% year over year) with net income of −$134M.
Q3 2026 key financials · XBRL
- Revenue
- $307,000
- −96.8% YoY · −37.3% QoQ
- Net income
- −$134M
- −19.2% YoY · −9.6% QoQ
- Operating margin
- -46033.2%
- EPS (diluted)
- −$1.29
- −18.3% YoY · −9.3% QoQ
Source: XBRL data from the Beam Therapeutics Inc. (BEAM) Q3 2026 10-Q on SEC EDGAR. USD.
Beam Therapeutics Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0.3M, down $9.4M from $9.7M YoY
- Net loss $134.4M vs $112.6M YoY, operating loss $141.3M vs $126.8M
- R&D expense $110.1M vs $109.8M, G&A $31.5M vs $26.7M
- Cash, equivalents and marketable securities $1.0B; operating cash outflow $305.4M
- BEAM-302 expansion ongoing, pivotal-cohort dosing expected complete in first half of 2027; additional capital likely needed
Risk Factors
- No material risk-factor changes identified relative to the 2025 Form 10-K
- Financing risk: $100.4 million debt outstanding at 10.6% effective interest, maturing February 24, 2033
- Liquidity risk: $1.0 billion cash, equivalents, and marketable securities expected to fund operations for at least 12 months
- Regulatory risk: risto-cel development and commercialization subject to FDA acceptance and approval milestones
- Collaboration risk: Biogen termination of FcRN program rights effective December 2026 ઘટાડે future collaboration potential
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Beam Therapeutics Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.